INMB

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

INmune Bio Inc

NASDAQ | INMB

1.89

USD

$0.00

(

0.00%

)

At Close (As of Oct 21, 2025)

$51.04M

Market Cap

-

P/E Ratio

-2.58

EPS

$10.50

52 Week High

$1.71

52 Week Low

HEALTHCARE

Sector

INMB Chart

Recent Chart
Price Action

INMB Technicals

Tags:

INMB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $14K
Total Revenue $14K
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$43M
Selling General And Administrative $9.5M
Research And Development $33M
Operating Expenses $43M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $553K
Income Before Tax -$42M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$42M
Comprehensive Income Net Of Tax -
Ebit -$43M
Ebitda -$42M
Net Income -$42M

Revenue & Profitability

Earnings Performance

INMB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $40M
Total Current Assets $23M
Cash And Cash Equivalents At Carrying Value $21M
Cash And Short Term Investments $21M
Inventory -
Current Net Receivables $1.4M
Total Non Current Assets $17M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $17M
Intangible Assets Excluding Goodwill $17M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $331K
Other Non Current Assets -
Total Liabilities $7.5M
Total Current Liabilities $7.2M
Current Accounts Payable $6.6M
Deferred Revenue -
Current Debt -
Short Term Debt $140K
Total Non Current Liabilities $244K
Capital Lease Obligations $384K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $384K
Other Current Liabilities $517K
Other Non Current Liabilities -
Total Shareholder Equity $32M
Treasury Stock -
Retained Earnings -$163M
Common Stock $22K
Common Stock Shares Outstanding $20M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$33M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $18M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$42M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $14K
Total Revenue $14K
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$43M
Selling General And Administrative $9.5M
Research And Development $33M
Operating Expenses $43M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $553K
Income Before Tax -$42M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$42M
Comprehensive Income Net Of Tax -
Ebit -$43M
Ebitda -$42M
Net Income -$42M

INMB News

INMB Profile

INmune Bio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

INmune Bio Inc., based in La Jolla, California, is a pioneering clinical-stage immunotherapy company focusing on reprogramming the innate immune system to tackle challenging diseases such as cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. With a promising pipeline of innovative therapies, INmune Bio is strategically positioned to lead advancements in immunotherapy, leveraging the body’s natural defenses to achieve better clinical outcomes. The company’s unwavering commitment to addressing critical unmet medical needs reflects its dedication to enhancing healthcare and improving the quality of life for patients globally.

BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
DVLT
+4.54%
$2.52
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
IBIO
+24.30%
$1.11
GSIT
-16.26%
$10.86
RIG
+0.60%
$3.31
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
GOOGL
-2.37%
$250.46
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
LAES
-5.86%
$6.10
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
IREN
-6.79%
$55.19
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
GPUS
-7.57%
$0.36
DCGO
+24.16%
$1.49
MARA
-3.18%
$20.07
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
SNAP
+1.55%
$7.85
PBR
-1.11%
$11.56
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
WTO
+2.93%
$0.06
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
EPWK
-8.71%
$0.07
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
IONQ
-0.73%
$59.50
MSN
+59.31%
$0.76
BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
DVLT
+4.54%
$2.52
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
IBIO
+24.30%
$1.11
GSIT
-16.26%
$10.86
RIG
+0.60%
$3.31
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
GOOGL
-2.37%
$250.46
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
LAES
-5.86%
$6.10
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
IREN
-6.79%
$55.19
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
GPUS
-7.57%
$0.36
DCGO
+24.16%
$1.49
MARA
-3.18%
$20.07
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
SNAP
+1.55%
$7.85
PBR
-1.11%
$11.56
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
WTO
+2.93%
$0.06
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
EPWK
-8.71%
$0.07
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
IONQ
-0.73%
$59.50
MSN
+59.31%
$0.76
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.